Staphylococcal vaccine development: Review of past failures and plea for a future evaluation of vaccine efficacy not only on staphylococcal infections but also on mucosal carriage

Expert Review of Vaccines

Volumn 12, Issue 11, 2013, Pages 1249-1259

  Botelho Nevers, Elisabeth ^a,b   Verhoeven, Paul ^a   Paul, Stephane ^a,b   Grattard, Florence ^a   Pozzetto, Bruno ^a   Berthelot, Philippe ^a   Lucht, Frederic ^a,b  

^a UNIVERSITÉ JEAN MONNET   (France)

^b HÔPITAL NORD   (France)

Author keywords

carriage; decolonization; immune evasion; Staphylococcus aureus; vaccine

Indexed keywords

ALPHA HEMOLYSIN; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CAPSULAR POLYSACCHARIDE 5; CAPSULAR POLYSACCHARIDE 8; COLLAGEN BINDING PROTEIN; EXTRACELLULAR ADHERENCE PROTEIN; INTERLEUKIN 17; INTERLEUKIN 17F; IRON SURFACE DETERMINANT B ANTIGEN; PSEUDOMONAL EXOPROTEIN A; STAPHYLOCOCCUS AUREUS 3 ANTIGEN; STAPHYLOCOCCUS AUREUS 4 ANTIGEN; STAPHYLOCOCCUS VACCINE; TEICHOIC ACID; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; BACTERIAL VIRULENCE; CARDIOVASCULAR SURGERY; CLINICAL RESEARCH; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FOLLOW UP; HEART SURGERY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOGENICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTICENTER STUDY (TOPIC); NONHUMAN; ORTHOPEDIC IMPLANT; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; SYSTEMATIC REVIEW; THORAX SURGERY; TREATMENT RESPONSE; VACCINATION; WOUND INFECTION;

BACTEREMIA; CARRIER STATE; CLINICAL TRIALS AS TOPIC; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS;

EID: 84887323412     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.840091     Document Type: Review

References (100)

1. Lowy FD. Staphylococcus aureus infections. N. Engl. J. Med. 339(8), 520-532 (1998
2. David MZ, Daum RS. Community-Associated methicillin-resistant Staphylococcus aureus: Epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 23(3), 616-687 (2010
3. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin. Infect. Dis. 54(4), 560-567 (2012
4. Noskin GA, Rubin RJ, Schentag JJ et al. National trends in Staphylococcus aureus infection rates: Impact on economic burden and mortality over a 6-year period (1998-2003). Clin. Infect. Dis. 45(9), 1132-1140 (2007
5. Wertheim HF, Vos MC, Ott A et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 364(9435), 703-705 (2004
6. Kluytmans J, van BA, Verbrugh H. Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 10(3), 505-520 (1997
7. Perl TM, Cullen JJ, Wenzel RP et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N. Engl. J. Med. 346(24), 1871-1877 (2002
8. Berthelot P, Grattard F, Cazorla C et al. Is nasal carriage of Staphylococcus aureus the main acquisition pathway for surgical-site infection in orthopaedic surgery? Eur. J. Clin. Microbiol. Infect. Dis. 29(4), 373-382 (2010
9. Kluytmans JA, Mouton JW, Ijzerman EP et al. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J. Infect. Dis. 171(1), 216-219 (1995
10. Pujol M, Pena C, Pallares R et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am. J. Med. 100(5), 509-516 (1996
11. Corbella X, Dominguez MA, Pujol M et al. Staphylococcus aureus nasal carriage as a marker for subsequent staphylococcal infections in intensive care unit patients. Eur. J. Clin. Microbiol. Infect. Dis. 16(5), 351-357 (1997
12. Aktas E, Pazarli O, Kulah C, Comert F, Kulah E, Sumbuloglu V. Determination of Staphylococcus aureus carriage in hemodialysis and peritoneal dialysis patients and evaluation of the clonal relationship between carriage and clinical isolates. Am. J. Infect. Control 39(5), 421-425 (2011
13. Nouwen J, Schouten J, Schneebergen P et al. Staphylococcus aureus carriage patterns and the risk of infections associated with continuous peritoneal dialysis. J. Clin. Microbiol. 44(6), 2233-2236 (2006
14. Nielsen J, Ladefoged SD, Kolmos HJ. Dialysis catheter-related septicaemia-focus on Staphylococcus aureus septicaemia. Nephrol. Dial. Transplant. 13(11), 2847-2852 (1998
15. Nguyen MH, Kauffman CA, Goodman RP et al. Nasal carriage of and infection with Staphylococcus aureus in HIV-infected patients. Ann. Intern. Med. 130(3), 221-225 (1999
16. Squier C, Rihs JD, Risa KJ et al. Staphylococcus aureus rectal carriage and its association with infections in patients in a surgical intensive care unit and a liver transplant unit. Infect. Control Hosp. Epidemiol. 23(9), 495-501 (2002
17. Safdar N, Bradley EA. The risk of infection after nasal colonization with Staphylococcus aureus. Am. J. Med. 121(4), 310-315 (2008
18. Simor AE. Staphylococcal decolonisation: An effective strategy for prevention of infection? Lancet Infect. Dis. 11(12), 952-962 (2011
19. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, Dágata EM. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: A meta-Analysis. Clin. Infect. Dis. 37(12), 1629-1638 (2003
20. Bode LG, Kluytmans JA, Wertheim HF et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N. Engl. J. Med. 362(1), 9-17 (2010
21. Walsh EE, Greene L, Kirshner R. Sustained reduction in methicillin-resistant Staphylococcus aureus wound infections after cardiothoracic surgery. Arch. Intern. Med. 171(1), 68-73 (2011
22. Wertheim HF, Vos MC, Ott A et al. Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: A randomized study. Ann. Intern. Med. 140(6), 419-425 (2004
23. Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM et al. Surgical site infections in orthopedic surgery: The effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin. Infect. Dis. 35(4), 353-358 (2002
24. Courville XF, Tomek IM, Kirkland KB, Birhle M, Kantor SR, Finlayson SR. Cost-effectiveness of preoperative nasal mupirocin treatment in preventing surgical site infection in patients undergoing total hip and knee arthroplasty: A cost-effectiveness analysis. Infect. Control Hosp. Epidemiol. 33(2), 152-159 (2012
25. Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clin. Infect. Dis. 49(6), 935-941 (2009
26. Wang JT, Sheng WH, Wang JL et al. Longitudinal analysis of chlorhexidine susceptibilities of nosocomial methicillin-resistant Staphylococcus aureus isolates at a teaching hospital in Taiwan. J. Antimicrob. Chemother. 62(3), 514-517 (2008
27. Fattom AI, Sarwar J, Ortiz A, Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. 64(5), 1659-1665 (1996
28. Shinefield H, Black S, Fattom A et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346(7), 491-496 (2002
29. Creech CB, Johnson BG, Alsentzer AR, Hohenboken M, Edwards KM, Talbot TR III. Vaccination as infection control: A pilot study to determine the impact of Staphylococcus aureus vaccination on nasal carriage. Vaccine 28(1), 256-260 (2009
30. Pishchany G, McCoy AL, Torres VJ et al. Specificity for human hemoglobin enhances Staphylococcus aureus infection. Cell Host. Microbe. 8(6), 544-550 (2010
31. Kuklin NA, Clark DJ, Secore S et al. A novel Staphylococcus aureus vaccine: Iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun. 74(4), 2215-2223 (2006
32. Etz H, Minh DB, Henics T et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl Acad. Sci. USA 99(10), 6573-6578 (2002
33. Zorman JK, Esser M, Raedler M et al. Naturally occurring IgG antibody levels to the Staphylococcus aureus protein IsdB in humans. Hum. Vaccin. Immunother. 9(9), doi:10.4161/hv.25253 (2013) (Epub ahead of print
34. Patti JM. Will we ever see the approval of a Staphylococcus aureus vaccine? Expert Rev. Anti. Infect. Ther. 9(10), 845-846 (2011
35. Fowler VG, Allen KB, Moreira ED et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: A randomized trial. JAMA 309(13), 1368-1378 (2013
36. Maira-Litran T, Kropec A, Abeygunawardana C et al. Immunochemical properties of the staphylococcal poly-N-Acetylglucosamine surface polysaccharide. Infect. Immun. 70(8), 4433-4440 (2002
37. Skurnik D, Kropec A, Roux D, Theilacker C, Huebner J, Pier GB. Natural antibodies in normal human serum inhibit staphylococcus aureus capsular polysaccharide vaccine efficacy. Clin. Infect. Dis. 55(9), 1188-1197 (2012
38. Skurnik D, Merighi M, Grout M et al. Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice. J. Clin. Invest 120(9), 3220-3233 (2010
39. Nanra JS, Buitrago SM, Crawford S et al. Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum. Vaccin. Immunother. 9(3), doi:10.4161/hv.23223 (2012) (Epub ahead of print
40. Grigg JC, Ukpabi G, Gaudin CF, Murphy ME. Structural biology of heme binding in the Staphylococcus aureus Isd system. J. Inorg. Biochem. 104(3), 341-348 (2010
41. Hurd AF, Garcia-Lara J, Rauter Y, Cartron M, Mohamed R, Foster SJ. The iron-regulated surface proteins IsdA, IsdB, and IsdH are not required for heme iron utilization in Staphylococcus aureus. FEMS Microbiol. Lett. 329(1), 93-100 (2012
42. Hawkins J, Kodali S, Matsuka YV et al. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clin. Vaccine Immunol. 19(10), 1641-1650 (2012
43. Novick RP. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol. Microbiol. 48(6), 1429-1449 (2003
44. Wertheim HF, Walsh E, Choudhurry R et al. Key role for clumping factor B in Staphylococcus aureus nasal colonization of humans. PLoS Med. 5(1), e17 (2008
45. Tong A, Tong SY, Zhang Y et al. Panton-Valentine leukocidin is not the primary determinant of outcome for Staphylococcus aureus skin infections: Evaluation from the CANVAS studies. PLoS ONE 7(5), e37212 (2012
46. Kahl BC, Belling G, Becker P et al. Thymidine-dependent Staphylococcus aureus small-colony variants are associated with extensive alterations in regulator and virulence gene expression profiles. Infect. Immun. 73(7), 4119-4126 (2005
47. Gagnaire J, Dauwalder O, Boisset S et al. Detection of Staphylococcus aureus delta-Toxin production by whole-cell MALDI-TOF mass spectrometry. PLoS ONE 7(7), e40660 (2012
48. Luedicke C, Slickers P, Ehricht R, Monecke S. Molecular fingerprinting of Staphylococcus aureus from bone and joint infections. Eur. J. Clin. Microbiol. Infect. Dis. 29(4), 457-463 (2010
49. Lina G, Piemont Y, Godail-Gamot F et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis. 29(5), 1128-1132 (1999
50. Spellberg B, Ibrahim AS, Yeaman MR et al. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect. Immun. 76(10), 4574-4580 (2008
51. Verkaik NJ, Benard M, Boelens HA et al. Immune evasion cluster-positive bacteriophages are highly prevalent among human Staphylococcus aureus strains, but they are not essential in the first stages of nasal colonization. Clin. Microbiol. Infect. 17(3), 343-348 (2011
52. Rooijakkers SH, Ruyken M, Roos A et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 6(9), 920-927 (2005
53. Rooijakkers SH, van Kessel KP, van Strijp JA. Staphylococcal innate immune evasion. Trends Microbiol. 13(12), 596-601 (2005
54. van Wamel WJ, Rooijakkers SH, Ruyken M, van Kessel KP, van Strijp JA. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of Staphylococcus aureus are located on beta-hemolysin- converting bacteriophages. J. Bacteriol. 188(4), 1310-1315 (2006
55. Postma B, Poppelier MJ, van Galen JC et al. Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor. J. Immunol. 172(11), 6994-7001 (2004
56. Rahimpour R, Mitchell G, Khandaker MH et al. Bacterial superantigens induce down-modulation of CC chemokine responsiveness in human monocytes via an alternative chemokine ligand-independent mechanism. J. Immunol. 162(4), 2299-2307 (1999
57. Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, Tarkowski A. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J. Immunol. 172(2), 1169-1176 (2004
58. Abel J, Goldmann O, Ziegler C et al. Staphylococcus aureus evades the extracellular antimicrobial activity of mast cells by promoting its own uptake. J. Innate. Immun. 3(5), 495-507 (2011
59. Brown EL, Dumitrescu O, Thomas D et al. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin. Microbiol. Infect. 15(2), 156-164 (2009
60. Quinn GA, Cole AM. Suppression of innate immunity by a nasal carriage strain of Staphylococcus aureus increases its colonization on nasal epithelium. Immunology 122(1), 80-89 (2007
61. Cole AM, Tahk S, Oren A et al. Determinants of Staphylococcus aureus nasal carriage. Clin. Diagn. Lab Immunol. 8(6), 1064-1069 (2001
62. Quinn GA, Tarwater PM, Cole AM. Subversion of interleukin-1-mediated host defence by a nasal carrier strain of Staphylococcus aureus. Immunology 128(1 Suppl.), e222-e229 (2009
63. Muthukrishnan G, Quinn GA, Lamers RP et al. Exoproteome of Staphylococcus aureus reveals putative determinants of nasal carriage. J. Proteome. Res. 10(4), 2064-2078 (2011
64. Burnside K, Lembo A, Harrell MI et al. Vaccination With a UV-irradiated genetically attenuated Mutant of Staphylococcus aureus Provides protection against subsequent systemic infection. J. Infect. Dis. 206(11), 1734-1744 (2012
65. Andrews WW, Schelonka R, Waites K, Stamm A, Cliver SP, Moser S. Genital tract methicillin-resistant Staphylococcus aureus: Risk of vertical transmission in pregnant women. Obstet. Gynecol. 111(1), 113-118 (2008
66. Quinti I, Soresina A, Spadaro G et al. Long-Term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J. Clin. Immunol. 27(3), 308-316 (2007
67. Oksenhendler E, Gerard L, Fieschi C et al. Infections in 252 patients with common variable immunodeficiency. Clin. Infect. Dis. 46(10), 1547-1554 (2008
68. Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G. Chronic granulomatous disease: A review of the infectious and inflammatory complications. Clin. Mol. Allergy 9(1), 10 (2011
69. Hartl D, Lehmann N, Hoffmann F et al. Dysregulation of innate immune receptors on neutrophils in chronic granulomatous disease. J. Allergy Clin. Immunol. 121(2), 375-382 (2008
70. Milner JD, Brenchley JM, Laurence A et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452(7188), 773-776 (2008
71. Ma CS, Chew GY, Simpson N et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 205(7), 1551-1557 (2008
72. Ishigame H, Kakuta S, Nagai T et al. Differential roles of interleukin-17A and-17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 30(1), 108-119 (2009
73. Puel A, Cypowyj S, Bustamante J et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332(6025), 65-68 (2011
74. Nembrini C, Marsland BJ, Kopf M. IL-17-producing T cells in lung immunity and inflammation. J. Allergy Clin. Immunol. 123(5), 986-994 (2009
75. Cho JS, Pietras EM, Garcia NC et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J. Clin. Invest 120(5), 1762-1773 (2010
76. Lin L, Ibrahim AS, Xu X et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 5(12), e1000703 (2009
77. Archer NK, Harro JM, Shirtliff ME. Clearance of Staphylococcus aureus nasal carriage is T-cell dependent and mediated through IL-17A expression and neutrophil influx. Infect. Immun. 81(6), 2070-2075 (2013
78. Projan SJ, Nesin M, Dunman PM. Staphylococcal vaccines and immunotherapy: To dream the impossible dream? Curr. Opin. Pharmacol. 6(5), 473-479 (2006
79. Kim HK, Kim HY, Schneewind O, Missiakas D. Identifying protective antigens of Staphylococcus aureus, a pathogen that suppresses host immune responses. FASEB J. 25(10), 3605-3612 (2011
80. Sabat A, Melles DC, Martirosian G, Grundmann H, van BA, Hryniewicz W. Distribution of the serine-Aspartate repeat protein-encoding sdr genes among nasal-carriage and invasive Staphylococcus aureus strains. J. Clin. Microbiol. 44(3), 1135-1138 (2006
81. Adhikari RP, Karauzum H, Sarwar J et al. Novel structurally designed vaccine for S. aureus alpha-hemolysin: Protection against bacteremia and pneumonia. PLoS ONE 7(6), e38567 (2012
82. Seib KL, Zhao X, Rappuoli R. Developing vaccines in the era of genomics: A decade of reverse vaccinology. Clin. Microbiol. Infect. 18(Suppl. 5), 109-116 (2012
83. Oprea M, Antohe F. Reverse-vaccinology strategy for designing T-cell epitope candidates for Staphylococcus aureus endocarditis vaccine. Biologicals 41(3), 148-153 (2013
84. Patti JM. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 22(Suppl. 1), S39-S43 (2004
85. Liu C, Graber CJ, Karr M et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin. Infect. Dis. 46(11), 1637-1646 (2008
86. Duffy J, Dumyati G, Bulens S et al. Community-onset invasive methicillin-resistant Staphylococcus aureus infections following hospital discharge. Am. J. Infect. Control 41(9), 782-786 (2013
87. Pier GB. Will there ever be a universal Staphylococcus aureus vaccine? Hum. Vaccin. Immunother. 9(9) (2013
88. Acton DS, Plat-Sinnige MJ, van WW, de GN, van BA. Intestinal carriage of Staphylococcus aureus: How does its frequency compare with that of nasal carriage and what is its clinical impact? Eur. J. Clin. Microbiol. Infect. Dis. 28(2), 115-127 (2009
89. Mertz D, Frei R, Jaussi B et al. Throat swabs are necessary to reliably detect carriers of Staphylococcus aureus. Clin. Infect. Dis. 45(4), 475-477 (2007
90. Verhoeven PO, Grattard F, Carricajo A et al. An algorithm based on one or two nasal samples is accurate to identify persistent nasal carriers of Staphylococcus aureus. Clin. Microbiol. Infect. 18(6), 551-557 (2012
91. Nouwen JL, Fieren MW, Snijders S, Verbrugh HA, van BA. Persistent (not intermittent) nasal carriage of Staphylococcus aureus is the determinant of CPD-related infections. Kidney Int. 67(3), 1084-1092 (2005
92. van Belkum A, Verkaik NJ, de Vogel CP et al. Reclassification of Staphylococcus aureus nasal carriage types. J. Infect. Dis. 199(12), 1820-1826 (2009
93. Kalmeijer MD, van Nieuwland-Bollen E, Bogaers-Hofman D, de Baere GA. Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery. Infect. Control Hosp. Epidemiol. 21(5), 319-323 (2000
94. Verhoeven PO, Grattard F, Carricajo A et al. Quantification by real-Time PCR assay of Staphylococcus aureus load: A useful tool for rapidly identifying persistent nasal carriers. J. Clin. Microbiol. 50(6), 2063-2065 (2012
95. Roca A, Bottomley C, Hill PC et al. Effect of age and vaccination with a pneumococcal conjugate vaccine on the density of pneumococcal nasopharyngeal carriage. Clin. Infect. Dis. 55(6), 816-824 (2012
96. Lu YJ, Gross J, Bogaert D et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 4(9), e1000159 (2008
97. Lemon KP, Klepac-Ceraj V, Schiffer HK, Brodie EL, Lynch SV, Kolter R. Comparative analyses of the bacterial microbiota of the human nostril and oropharynx. mBio. 1(3), e00129-10 (2010
98. Frank DN, Feazel LM, Bessesen MT, Price CS, Janoff EN, Pace NR. The human nasal microbiota and Staphylococcus aureus carriage. PLoS ONE 5(5), e10598 (2010
99. Iwase T, Uehara Y, Shinji H et al. Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature 465(7296), 346-349 (2010
100. Dunne EM, Smith-Vaughan HC, Robins-Browne RM, Mulholland EK, Satzke C. Nasopharyngeal microbial interactions in the era of pneumococcal conjugate vaccination. Vaccine 31(19), 2333-2342 (2013